Business

Augurex Announces Mayo Clinic Laboratories Now Offering 14-3-3eta Testing for Rheumatoid Arthritis

Financial Post · September 15, 2026 at 7:12 a.m.

Mayo Clinic Laboratories adds 14-3-3eta serum testing to its diagnostic testing portfolio, expanding access to an important biomarker for rheumatoid arthritis VANCOUVER, British Columbia — Augurex Life Sciences Corp., a

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Augurex Announces Mayo Clinic Laboratories Now Offering 14-3-3eta Testing for Rheumatoid Arthritis

More from Financial Post

Flame collected in Turin as Changchun prepares to welcome 2027 Winter Universiade

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

More in Business

Canada can't launch rockets on its own. A handful of companies want to change that

Flame collected in Turin as Changchun prepares to welcome 2027 Winter Universiade

PALESTINIAN REFORM ADVOCATE SAMER SINIJLAWI TELLS THE NEWS FORUM: ‘88% of eligible Palestinian voters have already preregistered for the November 28th election — the first election since 2005’

ModelFront Announces OpenLoc, the Open TMS Built for AI

PRU Quarterly Report Investor Webinar

EasyPark Receives Three Awards at Canadian Parking Association Conference